Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer
Authors
Keywords
-
Journal
OncoImmunology
Volume 8, Issue 12, Pages e1674605
Publisher
Informa UK Limited
Online
2019-10-12
DOI
10.1080/2162402x.2019.1674605
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- EGFR exon 21 L858R as an acquired resistance mechanism to nivolumab in a lung cancer patient originally driver gene-negative
- (2019) Chen Xia et al. Thoracic Cancer
- Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
- (2019) Chrétien et al. Cancers
- CD155 expression and its prognostic value in postoperative patients with breast cancer
- (2019) Hongmei Yong et al. BIOMEDICINE & PHARMACOTHERAPY
- CD155 expression in human breast cancer: Clinical significance and relevance to natural killer cell infiltration
- (2019) Hana Triki et al. LIFE SCIENCES
- Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
- (2018) Hope S. Rugo et al. CLINICAL CANCER RESEARCH
- Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option
- (2018) Hauke Stamm et al. ONCOGENE
- Gyneco-oncological genomics and emerging biomarkers for cancer treatment with immune-checkpoint inhibitors
- (2018) Giuseppe Curigliano SEMINARS IN CANCER BIOLOGY
- A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer
- (2018) Zhixian Liu et al. Translational Oncology
- PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer
- (2018) Magalie Dosset et al. OncoImmunology
- Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation
- (2018) Shan Su et al. Journal of Thoracic Oncology
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up
- (2018) Sylvia Adams et al. JAMA Oncology
- TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy
- (2017) William C. Dougall et al. IMMUNOLOGICAL REVIEWS
- Emerging targets in cancer immunotherapy
- (2017) Samantha Burugu et al. SEMINARS IN CANCER BIOLOGY
- Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping
- (2017) Xiaofeng Dai et al. Journal of Cancer
- Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy
- (2017) Xingchun Gao et al. Frontiers in Immunology
- Ten-year survival in women with primary stage IV breast cancer
- (2016) Lee Guek Eng et al. BREAST CANCER RESEARCH AND TREATMENT
- Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial
- (2016) Denise A. Yardley et al. Clinical Breast Cancer
- T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients
- (2016) Y. Kong et al. CLINICAL CANCER RESEARCH
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase
- (2016) Takashi Inozume et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts
- (2016) Judith Feucht et al. Oncotarget
- TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients
- (2015) Joe-Marc Chauvin et al. JOURNAL OF CLINICAL INVESTIGATION
- TIGIT predominantly regulates the immune response via regulatory T cells
- (2015) Sema Kurtulus et al. JOURNAL OF CLINICAL INVESTIGATION
- Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab
- (2015) Thomas Köhnke et al. Journal of Hematology & Oncology
- Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism
- (2015) C Krupka et al. LEUKEMIA
- Clinical overview of anti-CD19 BiTE® and ex vivo data from anti-CD33 BiTE® as examples for retargeting T cells in hematologic malignancies
- (2015) Gerhard Zugmaier et al. MOLECULAR IMMUNOLOGY
- Combination cancer immunotherapies tailored to the tumour microenvironment
- (2015) Mark J. Smyth et al. Nature Reviews Clinical Oncology
- PROGgeneV2: enhancements on the existing database
- (2015) Chirayu Pankaj Goswami et al. BMC CANCER
- Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
- (2014) S. Loi et al. ANNALS OF ONCOLOGY
- Prognostic relevance of glycosylation-associated genes in breast cancer
- (2014) Karin Milde-Langosch et al. BREAST CANCER RESEARCH AND TREATMENT
- The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
- (2014) Robert J. Johnston et al. CANCER CELL
- TIGIT and CD226: Tipping the Balance between Costimulatory and Coinhibitory Molecules to Augment the Cancer Immunotherapy Toolkit
- (2014) Kristen E. Pauken et al. CANCER CELL
- T-cell Immunoglobulin and ITIM Domain (TIGIT) Receptor/Poliovirus Receptor (PVR) Ligand Engagement Suppresses Interferon-γ Production of Natural Killer Cells via β-Arrestin 2-mediated Negative Signaling
- (2014) Man Li et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The prognostic significance of Jun transcription factors in ovarian cancer
- (2013) Kerstin Eckhoff et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy
- (2013) Margaret K. Callahan et al. JOURNAL OF LEUKOCYTE BIOLOGY
- TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
- (2012) Lisa A. Carey et al. JOURNAL OF CLINICAL ONCOLOGY
- The TIGIT/CD226 Axis Regulates Human T Cell Function
- (2012) E. Lozano et al. JOURNAL OF IMMUNOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity
- (2011) Emilie Mamessier et al. JOURNAL OF CLINICAL INVESTIGATION
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
- (2009) M. Ahmadzadeh et al. BLOOD
- Primary Human Tumor Cells Expressing CD155 Impair Tumor Targeting by Down-Regulating DNAM-1 on NK Cells
- (2009) M. Carlsten et al. JOURNAL OF IMMUNOLOGY
- The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
- (2009) N. Stanietsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Epidemiology of Locally Advanced Breast Cancer
- (2009) Lisa A. Newman SEMINARS IN RADIATION ONCOLOGY
- Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer
- (2008) Maura N. Dickler et al. BREAST CANCER RESEARCH AND TREATMENT
- C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma
- (2008) S Mahner et al. BRITISH JOURNAL OF CANCER
- A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer
- (2008) M. N. Dickler et al. CLINICAL CANCER RESEARCH
- The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
- (2008) Xin Yu et al. NATURE IMMUNOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started